Concurrently, the current literature showed the presence of mTORC1 pathway alteration (TSC1/TSC2/mTOR/RHEB) in a number of recently described renal tumors [9] in patients without TSC mutations (i.e., in sporadic tumors in patients without germinal mutation of TSC1 or TSC2). This evidence concerns the gene TSC1 and kidney neoplasm.